Emergent BioSolutions Inc. (NYSE:EBS – Get Free Report) was the recipient of a significant increase in short interest in March. As of March 31st, there was short interest totalling 5,700,000 shares, an increase of 16.1% from the March 15th total of 4,910,000 shares. Currently, 11.4% of the shares of the stock are short sold. Based on an average trading volume of 2,980,000 shares, the days-to-cover ratio is currently 1.9 days.
Emergent BioSolutions Trading Down 5.9 %
Shares of EBS stock traded down $0.13 during mid-day trading on Friday, reaching $2.06. 1,008,941 shares of the stock traded hands, compared to its average volume of 1,187,517. The stock’s fifty day simple moving average is $2.37 and its two-hundred day simple moving average is $2.31. Emergent BioSolutions has a 1-year low of $1.42 and a 1-year high of $12.94. The company has a quick ratio of 0.54, a current ratio of 1.04 and a debt-to-equity ratio of 0.69. The company has a market cap of $107.54 million, a price-to-earnings ratio of -0.14 and a beta of 1.20.
Emergent BioSolutions (NYSE:EBS – Get Free Report) last posted its earnings results on Wednesday, March 6th. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.44). The business had revenue of $276.60 million for the quarter, compared to the consensus estimate of $247.63 million. Emergent BioSolutions had a negative return on equity of 37.35% and a negative net margin of 72.11%. During the same period in the previous year, the firm earned ($0.31) earnings per share. On average, research analysts anticipate that Emergent BioSolutions will post -13.98 EPS for the current fiscal year.
Institutional Investors Weigh In On Emergent BioSolutions
Analyst Ratings Changes
Separately, Benchmark reaffirmed a “buy” rating and set a $5.00 price target on shares of Emergent BioSolutions in a report on Thursday.
Read Our Latest Stock Analysis on EBS
Emergent BioSolutions Company Profile
Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.
See Also
- Five stocks we like better than Emergent BioSolutions
- Using the MarketBeat Dividend Tax Calculator
- 5 Trends You Need to Know This Quarter
- Health Care Stocks Explained: Why You Might Want to Invest
- MarketBeat Week in Review – 4/8 – 4/12
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- You Can Follow BlackRock’s Market View for Your Money
Receive News & Ratings for Emergent BioSolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent BioSolutions and related companies with MarketBeat.com's FREE daily email newsletter.